A detailed history of Parkside Financial Bank & Trust transactions in Novo Cure LTD stock. As of the latest transaction made, Parkside Financial Bank & Trust holds 233 shares of NVCR stock, worth $4,131. This represents 0.0% of its overall portfolio holdings.

Number of Shares
233
Previous 282 17.38%
Holding current value
$4,131
Previous $4,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$15.61 - $23.34 $764 - $1,143
-49 Reduced 17.38%
233 $3,000
Q2 2024

Aug 05, 2024

BUY
$11.83 - $24.05 $993 - $2,020
84 Added 42.42%
282 $4,000
Q1 2024

May 01, 2024

SELL
$12.42 - $17.29 $211 - $293
-17 Reduced 7.91%
198 $3,000
Q4 2023

Feb 01, 2024

BUY
$11.13 - $15.78 $1,613 - $2,288
145 Added 207.14%
215 $3,000
Q3 2023

Nov 13, 2023

BUY
$16.15 - $42.35 $1,001 - $2,625
62 Added 775.0%
70 $1,000
Q2 2023

Aug 15, 2023

SELL
$40.29 - $82.51 $1,450 - $2,970
-36 Reduced 81.82%
8 $0
Q1 2023

May 04, 2023

SELL
$56.44 - $118.81 $112 - $237
-2 Reduced 4.35%
44 $2,000
Q3 2022

Nov 01, 2022

SELL
$67.99 - $89.57 $271 - $358
-4 Reduced 8.0%
46 $3,000
Q2 2022

Jul 13, 2022

BUY
$56.6 - $89.9 $679 - $1,078
12 Added 31.58%
50 $3,000
Q1 2022

May 13, 2022

BUY
$60.15 - $84.52 $300 - $422
5 Added 15.15%
38 $3,000
Q4 2021

Feb 14, 2022

BUY
$75.08 - $121.99 $1,801 - $2,927
24 Added 266.67%
33 $2,000
Q3 2021

Oct 29, 2021

SELL
$116.17 - $194.55 $3,949 - $6,614
-34 Reduced 79.07%
9 $1,000
Q2 2021

Aug 06, 2021

BUY
$130.4 - $225.58 $4,564 - $7,895
35 Added 437.5%
43 $10,000
Q4 2020

Feb 09, 2021

BUY
$112.16 - $174.14 $448 - $696
4 Added 100.0%
8 $2,000
Q3 2020

Nov 06, 2020

BUY
$58.05 - $111.31 $232 - $445
4 New
4 $0

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.86B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Parkside Financial Bank & Trust Portfolio

Follow Parkside Financial Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Parkside Financial Bank & Trust with notifications on news.